Biolife Solutions Inc (BLFS) · Oct 6, 2026 · Acquisition
$1.5B acquisition — $11.25 cash plus 0.1442 Repligen shares per BioLife share
BioLife Solutions’ acquisition by Repligen closes on the previously agreed terms, transferring the business and ending BLFS’s Nasdaq listing.
BioLife Solutions was being built as a biopreservation-media and cell-processing-tools platform for the cell-and-gene-therapy market, with products embedded in clinical trials and approved therapies; Repligen positioned the deal as a way to add those recurring consumables and deepen its cell-therapy offering.
The acquisition is now legally complete, not newly discovered. The filing confirms that Repligen completed the two-step merger on October 6, 2026, with BioLife becoming a wholly owned Repligen subsidiary. 〔0〕 The transaction had already been announced in July and was expected to close in the fourth quarter, so this removes execution risk rather than changing the strategic premise.
BioLife shareholders receive the agreed cash-and-stock consideration. Each BioLife share converted into $11.25 in cash plus 0.1442 Repligen shares, with equity awards accelerated and converted under the merger terms. 〔1〕 The filing does not introduce a revised price, financing complication, or renegotiation.
The event ends BioLife’s standalone public-company story. BioLife ceased to exist as a separate legal entity, its Nasdaq listing is being removed, its stockholder rights ended except for merger consideration or appraisal rights, and its board and named executive officers resigned. 〔2〕
The shareholder vote showed overwhelming approval, but it was a closing formality by this point. Holders representing 83.79% of eligible shares participated, and the merger received 40,910,337 votes for versus 83,451 against. 〔3〕
Bottom line: This filing completes the previously announced sale of BioLife to Repligen and ends BLFS as an independent listed company. It materially changes ownership and reporting status, but adds little surprise because the terms and closing were already public.
Repligen integration and BioLife operating updates
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!